Page last updated: 2024-12-08
riparin iii
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
riparin III: isolated from unripe Aniba riparia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Aniba | genus | [no description available] | Lauraceae | A family of mainly aromatic evergreen plants in the order Laurales. The laurel family includes 2,200 species in 45 genera and from these are derived medicinal extracts, essential oils, camphor and other products.[MeSH] |
Aniba riparia | species | [no description available] | Lauraceae | A family of mainly aromatic evergreen plants in the order Laurales. The laurel family includes 2,200 species in 45 genera and from these are derived medicinal extracts, essential oils, camphor and other products.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 182537 |
MeSH ID | M0232935 |
Synonyms (10)
Synonym |
---|
riparin |
2,6-dihydroxy-n-[2-(4-methoxyphenyl)ethyl]benzamide |
benzamide, 2,6-dihydroxy-n-(2-(4-methoxyphenyl)ethyl)- |
o-methyl-n-(2,6-dihydroxybenzoyl)tyramine |
riparin iii |
112356-54-4 |
2,6-dihydroxy-n-(2-(4-methoxyphenyl)ethyl)benzamide |
DTXSID50150004 |
2,6-dihydroxy-n-(4-methoxyphenethyl)benzamide |
AKOS040747395 |
Research Excerpts
Overview
Riparin III (Rip III) is an alcamide isolated from Aniba riparia. It has presented effects of antidepressant and anxiolytic activities in acute stress behavioral models.
Excerpt | Reference | Relevance |
---|---|---|
"Riparin III (Rip III) is an alcamide isolated from Aniba riparia that has presented effects of antidepressant and anxiolytic activities in acute stress behavioral models. " | ( Subchronic administration of riparin III induces antidepressive-like effects and increases BDNF levels in the mouse hippocampus. Barbosa-Filho, JM; de França Fonteles, MM; de Sousa, FC; Gaspar, DM; Gutierrez, SJ; Oliveira, IC; Rodrigues, GC; Vasconcelos, AS; Vasconcelos, SM; Vidal, LT, 2015) | 2.15 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 4 (36.36) | 29.6817 |
2010's | 4 (36.36) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.52
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.52) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |